SequelSEC

XBiotech Inc. XBIT

Pharmaceutical Preparations · CIK 0001626878 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2023-12-31
Operating income
-$37.51M
Fiscal year ended 2023-12-31
Free cash flow
-$19.09M
Fiscal year ended 2023-12-31

Valuation, from the filing

Public float$77.05MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.53Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-100.0%0th
Current ratio33.07x99th

XBiotech Inc. (XBIT) reported revenue of $0 and net income of -$24.56M for the fiscal year ended 2023-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from XBiotech Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

XBiotech Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Revenue$0
Cost of revenue$0
Gross profit$0
Operating income-$37.51M
Net income-$24.56M
Research & development$32.85M
Weighted-average diluted sharesUnavailable
Pretax income-$24.31M
Income tax expense$317.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$4.66M
Selling & marketingUnavailable

Balance

XBiotech Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Cash & equivalents$200.02M
Total assets$226.62M
Current assets$201.72M
Total liabilities$7.77M
Current liabilities$6.10M
Total equity incl. NCI$218.85M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$860.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$2.52M

Cash flow

XBiotech Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Operating cash flow-$18.72M
Capital expenditures$362.00K
Investing cash flow$61.50M
Financing cash flow-$9.00K
Net change in cash$42.72M
Stock-based compensation$3.26M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

XBiotech Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Free cash flow-$19.09M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio33.07x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open XBIT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-13View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.